ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

ANNALS OF ONCOLOGY driving innovation in oncology

SCLC

1410 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

N. Reinmuth[1], J.W. Goldman[2], M.C. Garassino[3], Y. Chen[4], K. Hotta[5], A. Poltoratskiy[6], D. Trukhin[7], M.J. Hochmair[8], J.H. Ji[9], M. Özgüroğlu[10], G. Statsenko[11], O. Voitko[12], N.V. Conev[13], I. Bondarenko[14], H. Mann[15], M. Xie[16], Y. Shrestha[17], P. Chugh[16], T. Dalvi[17], L. Paz-Ares[18]

[1]Asklepios Lung Clinic, Munich-Gauting, Germany; [2]David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; [3]Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and The University of Chicago, Chicago, IL, USA; [4]Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI, USA; [5]Okayama University Hospital, Okayama, Japan; [6]Petrov Research Institute of Oncology, St Petersburg, Russian Federation; [7]Odessa Regional Oncological Dispensary, Odessa, Ukraine; [8]Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria; [9]Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea; [10]Istanbul University–Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey; [11]Omsk Regional Cancer Center, Omsk, Russian Federation; [12]Kyiv City Clinical Oncological Centre, Kiev, Ukraine; [13]Clinic of Medical Oncology, UMHAT St Marina, Varna, Bulgaria; [14]Dnipropetrovsk Medical Academy, Dnipro, Ukraine; [15]AstraZeneca, Cambridge, UK; [16]AstraZeneca, Waltham, MA, USA; [17]AstraZeneca, Gaithersburg, MD, USA; [18]Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain

Background: In the phase 3 CASPIAN trial, 1L D+EP significantly improved OS vs EP and OS benefit was sustained after >3 years median follow-up (HR 0.71; 95% CI 0.60–0.86; nominal p=0.0003). Here we assess clinical and molecular characteristics of pts who experienced long-term survival in CASPIAN.

Methods: 805 pts with ES-SCLC were randomised 1:1:1 to D+EP, D+T+EP or EP. In post-hoc analyses, clinical characteristics were assessed in long-term survivors (LTS; n=94), defined as pts still alive at the 22 Mar 2021 data cutoff (DCO; median follow-up 39.4 mo). PD-L1 expression and tissue tumour mutational burden (tTMB) were assessed in the biomarker evaluable populations (BEPs) according to OS landmark (18 and 36 mo).

Results: There were 44 (16%), 37 (14%) and 13 (5%) LTS in the D+EP, D+T+EP and EP arms, respectively. LTS had slightly higher incidence of some favourable prognostic factors at baseline; incidence of brain/liver mets was lower among LTS vs ITT, although they still occurred in some LTS (Table). More LTS received ≥4 cycles EP than ITT, with a higher median overall treatment exposure in the IO+EP arms. 46 (27 D+EP; 19 D+T+EP) LTS were ongoing D treatment at this DCO. ORR and 24-mo PFS rates were higher for LTS vs ITT in the IO+EP arms. Rates of serious AEs (SAEs) were similar in LTS and ITT (Table). In the D+T+EP arm only, incidence of PD-L1 expression on ≥1% of tumour cells (TC) or immune cells (IC) (but not tTMB >10 mut/Mb) was enriched in pts with OS ≥18 mo vs OS <18 mo (Table); enrichment was maintained with OS ≥36 mo (data will be presented).

Conclusions: There were >3 times as many LTS in the D+EP arm vs the EP arm. LTS were more likely to have favourable prognostic characteristics than ITT, although some LTS had brain/liver mets at baseline. Notably, most LTS completed EP induction and, in both the IO+EP arms, had substantially greater overall treatment exposure, as well as achieving higher ORR and longer PFS, vs ITT. There was no evidence of cumulative toxicity based on SAEs.

Clinical trial identification: NCT03043872 (Release date February 6, 2017).

Editorial acknowledgement: Medical writing support for the development of this abstract, under the direction of the authors, was provided by Helen Kitchen of Ashfield MedComms (Macclesfield, UK), an Ashfield Health company, and was funded by AstraZeneca.

Legal entity responsible for the study: AstraZeneca PLC.

Funding: AstraZeneca.

Disclosure: N. Reinmuth: Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Boehringer-Ingelheim; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Hoffmann-La Roche; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Boehringer-Ingelheim; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Hoffmann-La Roche; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Takeda. J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca; Non-Financial Interests, Personal, Principal Investigator: Advaxis; Non-Financial Interests, Personal, Principal Investigator: Bristol Myers Squibb; Non-Financial Interests, Personal, Principal Investigator: Genentech; Non-Financial Interests, Personal, Principal Investigator: Pfizer; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Advaxis; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: Genentech; Financial Interests, Personal, Research Grant: Pfizer. M.C. Garassino: Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Other: MSD International GmbH; Financial Interests, Personal, Other: Bristol Myers Squibb; Financial Interests, Personal, Other: Boehringer Ingelheim Italia S.p.A; Financial Interests, Personal, Other: Celgene; Financial Interests, Personal, Other: Eli Lilly; Financial Interests, Personal, Other: Ignyta; Financial Interests, Personal, Other: Genetics; Financial Interests, Personal, Other: Mirati; Financial Interests, Personal, Other: Daiichi Sankyo; Financial Interests, Personal, Other: Regerenon; Financial Interests, Institutional, Other: Eli Lilly; Financial Interests, Institutional, Other: MSD; Financial Interests, Institutional, Other: Pfizer (MISP); Financial Interests, Institutional, Other: AstraZeneca; Financial Interests, Institutional, Other: MSD International GmbH; Financial Interests, Institutional, Other: Bristol Myers Squibb; Financial Interests, Institutional, Other: Boehringer Ingelheim Italia S.p.A; Financial Interests, Institutional, Other: Celgene; Financial Interests, Institutional, Other: Eli Lilly; Financial Interests, Institutional, Other: Ignyta; Financial Interests, Institutional, Other: Incyte; Financial Interests, Institutional, Other: MedImmune; Financial Interests, Institutional, Other: Novartis; Financial Interests, Institutional, Other: Pfizer; Financial Interests, Institutional, Other: Roche; Financial Interests, Institutional, Other: Takeda; Financial Interests, Institutional, Other: Tiziana; Financial Interests, Institutional, Other: Foundation Medicine; Financial Interests, Institutional, Other: Glaxo Smith Kline GSK; Financial Interests, Institutional, Other: Spectrum pharmaceuticals ; Financial Interests, Institutional, Research Grant: AIRC; Financial Interests, Institutional, Research Grant: AIFA; Financial Interests, Institutional, Research Grant: Italian Moh; Financial Interests, Institutional, Research Grant: TRANSCAN. Y. Chen: Financial Interests, Personal, Other, Honoraria: Amgen; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb; Financial Interests, Personal, Other, Honoraria: Guardant Health; Financial Interests, Personal, Other, Honoraria: Jazz Pharmaceutical; Financial Interests, Personal, Other, Honoraria:

Table: 1410

	D+EP		D+T+EP		EP	
	LTS	ITT	LTS	ITT	LTS	ITT
n	44	268	37	268	13	269
Median age, yrs	59.5	62	59	63	63	63
Male, %	50	71	70	75	54	68
PS 0, %	43	37	46	41	31	33
Brain mets, %	7	10	8	14	0	10
Liver mets, %	20	40	30	44	15	39
Median overall exposure, wks	159	28	160	23	20	19
D dose delays, %	75	57	76	59	–	–
≥4 cycles EP, %*	100	87	92	81	92	85
Unconfirmed ORR, %†	89	79	92	74	69	71
24-mo PFS, %†	65	11	67	12	55	3
SAEs, %	34	32	54	47	31	36
BEP, n/N (%)	OS ≥18 mo	OS <18 mo	OS ≥18 mo	OS <18 mo	OS ≥18 mo	OS <18 mo
PD-L1 (TC or IC) ≥1%	13/46 (28)	25/106 (24)	24/47 (51)	30/110 (27)	7/24 (29)	25/103 (24)
tTMB >10 mut/Mb	16/29 (55)	41/78 (53)	16/30 (53)	32/75 (43)	4/16 (25)	22/55 (40)

*Based on etoposide

†From 27 Jan 2020 DCO; RECIST data not collected after this DCO

Merck; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: Takeda; Financial Interests, Personal, Other, Research contract and support for meeting attendance/travel: Ipsen. K. Hotta: Financial Interests, Personal, Speaker's Bureau: Pfizer; Financial Interests, Personal, Speaker's Bureau: AstraZeneca; Financial Interests, Personal, Speaker's Bureau: Chugai; Financial Interests, Personal, Speaker's Bureau: Lilly; Financial Interests, Personal, Speaker's Bureau: Takeda; Financial Interests, Personal, Speaker's Bureau: MSD; Financial Interests, Personal, Speaker's Bureau: Bristol Myers Squibb; Financial Interests, Personal, Speaker's Bureau: Ono; Financial Interests, Personal, Speaker's Bureau: Taiho; Financial Interests, Personal, Speaker's Bureau: Boehringer-Ingelheim; Financial Interests, Personal, Research Grant: MSD; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Chugai; Financial Interests, Personal, Research Grant: Lilly; Financial Interests, Personal, Research Grant: Bristol Myers Squibb; Financial Interests, Personal, Research Grant: AbbVie. M.J. Hochmair: Financial Interests, Personal, Speaker's Bureau: AstraZeneca; Financial Interests, Personal, Speaker's Bureau: Bristol Myers Squibb; Financial Interests, Personal, Speaker's Bureau: Boehringer Ingelheim; Financial Interests, Personal, Speaker's Bureau: MSD; Financial Interests, Personal, Speaker's Bureau: Pfizer; Financial Interests, Personal, Speaker's Bureau: Roche; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Takeda. G. Statsenko: Financial Interests, Personal, Principal Investigator: AstraZeneca; Financial Interests, Personal, Principal Investigator: MCD; Financial Interests, Personal, Principal Investigator: AbbVie; Financial Interests, Personal, Principal Investigator: BeiGene. H. Mann: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. M. Xie: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. Y. Shrestha: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. P. Chugh: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. T. Dalvi: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. L. Paz-Ares: Financial Interests, Personal, Speaker's Bureau: AstraZeneca; Financial Interests, Personal, Speaker's Bureau: Jannsen; Financial Interests, Personal, Speaker's Bureau: Merck; Financial Interests, Personal, Speaker's Bureau: Mirati; Financial Interests, Personal, Speaker's Bureau: Lilly; Financial Interests, Personal, Speaker's Bureau: MSD; Financial Interests, Personal, Speaker's Bureau: Roche; Financial Interests, Personal, Speaker's Bureau: PharmaMar; Financial Interests, Personal, Speaker's Bureau: Merck; Financial Interests, Personal, Speaker's Bureau: Novartis; Financial Interests, Personal, Speaker's Bureau: Servier; Financial Interests, Personal, Speaker's Bureau: Amgen; Financial Interests, Personal, Speaker's Bureau: Pfizer; Financial Interests, Personal, Speaker's Bureau: Sanofi; Financial Interests, Personal, Speaker's Bureau: Bayer; Financial Interests, Personal, Speaker's Bureau: Bristol Myers Squibb; Financial Interests, Personal, Speaker's Bureau: GSK; Financial Interests, Personal, Speaker's Bureau: Takeda; Financial Interests, Personal, Member of the Board of Directors: Genomica; Financial Interests, Personal, Member of the Board of Directors: Altum sequency; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2022.02.172

142P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab

D. Isla[1], E. Arriola[2], M.R. Garcia Campelo[3], C. Martí[4], P. Diz Tain[5], A.L. Moreno Vega[6], M.L-B. Piqueras[7], L. León[8], V. Gutierrez Calderon[9], J.M. Oramas Rodriguez[10], M. Majem[11], A. Sanchez-Hernandez[12], C. Aguado de la Rosa[13], R. Alvarez Cabellos[14], J.L. Marti-Ciriquian[15], A. Moreno Paul[16], M. Gonzalez Cordero[17], Á. Callejo Mellén[18], L. Baez[18], J. Zugazagoitia[19]

[1]*Medical Oncology Department, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain;* [2]*Medical Oncology Dept., Hospital del Mar - Parc de Salut Mar, Barcelona, Spain;* [3]*Dept. Medical Oncology, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain;* [4]*Hospital Universitari de Sant Joan de Reus, Reus, Spain;* [5]*Complejo Asistencial Universitario de León, Leon, Spain;* [6]*Medical Oncology Department, Hospital Universitario Reina Sofía, Cordoba, Spain;* [7]*Hospital Universitario Marques de Valdecilla, Santander, Spain;* [8]*Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain;* [9]*Medical Oncology, Hospital Regional Universitario Málaga Carlos Haya, Malaga, Spain;* [10]*Hospital Universitario de Canarias, San Cristobal de La Laguna, Santa Cruz de Tenerife, Spain;* [11]*Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;* [12]*Consorcio Hospitalario Provincial de Castellón, Castellon de La Plana, Spain;* [13]*Hospital Universitario Clínico San Carlos, Madrid, Spain;* [14]*Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain;* [15]*Hospital General Universitario de Alicante, Alicante, Spain;* [16]*Hospital Galdako-Usansolo, Galdako, Spain;* [17]*Medical Oncology, Hospital Universitario de Badajoz, Badajoz, Spain;* [18]*AstraZeneca Farmacéutica Spain S.A., Madrid, Spain;* [19]*Medical Oncology Dept., Hospital Universitario 12 de Octubre, Madrid, Spain*

Background: Most patients (Pts) with small-cell lung cancer (SCLC) have extensive-stage (ES) disease at diagnosis, and poor prognosis. First-line durvalumab (D) plus platinum–etoposide (EP) significantly improved overall survival in pts with ES-SCLC versus control group in CASPIAN study. CANTABRICO will assess safety and effectiveness of D plus EP in a real world ES-SCLC population.

Methods: CANTABRICO is a phase IIIb, single arm, multicentre study (NCT04712903). Eligible Pts were ≥18 years old with treatment naive ES-SCLC, ECOG PS 0-2, with at least one measurable lesion. D (1500 mg) was concurrently administered with first-line cisplatin (CPT) or carboplatin (CP) d1 plus ET d1-3 every 3 weeks for 4 to 6 cycles (limited to 4 cycles in CASPIAN), and every 4 weeks thereafter until progressive disease or unacceptable toxicity.

Results: Between December 2020 and April 2021 101 Pts from 35 sites in Spain were included. At data cut-off (October 22nd 2021) all pts had finished chemotherapy. 56% of Pts were ≥ 65 years old, 67% were men, 94% had ECOG 0-1. 35%, 31% and 11% of Pts had liver, bone or brain metastases, respectively. 98% were current or former smokers and 10% had limited stage diagnosis. 85% of Pts completed ≥ 4 cycles, 41% ≥ 5 cycles and 32% 6 cycles of EP. Most Pts (89%) received CP-ET. Approximately half of the Pts had EP dose delays and a quarter dose reductions. Most frequent reason for EP dose delay/reduction were hematological toxicity (53%/63%). D was interrupted in 5 Pts due to nephritis (2), liver toxicity, rash and skin reaction. Seven Pts discontinued EP due to adverse events (6/7 before cycle 5): 1 respiratory infection; 1 kidney function impairment, atrial flutter, congestive heart failure and hypoxemia; 1 pneumonitis; 1 neutropenia; 1 thrombopenia, anemia and herpes zoster; 1 respiratory insufficiency and 1 thrombocytopenia, neutropenia and anemia.

Conclusions: CANTABRICO showed that increasing number of EP didn't have a detrimental effect as more than 40% were able to receive more than 4 cycles (32% 6 cycles), with only 1 Pt discontinued after cycle 5 due to toxicity. Most common AEs leading to treatment modification were hematological and due to EP.

Clinical trial identification: EudraCT 2020-002328-35; NCT04712903.

Editorial acknowledgement: Juan Luis Sanz (APICES) provided editorial assistance in the writing of the abstract.

Legal entity responsible for the study: AstraZeneca Farmaceutica Spain S.A.

Funding: AstraZeneca Farmacéutica Spain S.A.

Disclosure: D. Isla: Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Personal and Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal and Institutional, Invited Speaker: Roche; Financial Interests, Personal and Institutional, Invited Speaker: Roche; Financial Interests, Personal and Institutional, Advisory Board: Roche; Financial Interests, Personal and Institutional, Principal Investigator: Roche; Financial Interests, Personal and Institutional, Invited Speaker: Amgen; Financial Interests, Personal and Institutional, Advisory Board: Amgen; Financial Interests, Personal and Institutional, Principal Investigator: Amgen; Financial Interests, Personal and Institutional, Invited Speaker: Bayer; Financial Interests, Personal and Institutional, Advisory Board: Bayer; Financial Interests, Personal and Institutional, Invited Speaker: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Principal Investigator: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Invited Speaker: MSD; Financial Interests, Personal and Institutional, Advisory Board: MSD; Financial Interests, Personal and Institutional, Principal Investigator: MSD; Financial Interests, Personal and Institutional, Invited Speaker: Pfizer; Financial Interests, Personal and Institutional, Advisory Board: Pfizer; Financial Interests, Personal and Institutional, Invited Speaker: Takeda; Financial Interests, Personal and Institutional, Advisory Board: Takeda. E. Arriola: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Product Samples: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Research Grant: Roche; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Invited Speaker: Takeda. M.R. Garcia Campelo: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Principal Investigator: MSD; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb; Financial Interests, Personal, Principal Investigator: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Principal Investigator: Roche; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Principal Investigator: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Medscape Pfizer; Financial Interests, Personal, Invited Speaker: Medscape Pfizer; Financial Interests, Personal, Principal Investigator: Medscape Pfizer; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Principal Investigator: Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Principal Investigator: AstraZeneca; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Principal Investigator: Lilly; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Principal Investigator: Takeda; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Principal Investigator: Janssen. C. Martí: Financial Interests, Personal, Writing Engagements: MDS; Financial Interests, Personal, Invited Speaker: AstraZeneca. P. Diz Tain: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Bristol Myers Squibb; Financial Interests, Personal, Training: Bristol Myers Squibb; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca; Financial Interests, Personal and Institutional, Training: AstraZeneca; Financial Interests, Personal and Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim; Financial Interests, Personal, Training: Boehringer Ingelheim; Financial Interests, Personal and Institutional, Invited Speaker: Roche; Financial Interests, Personal and Institutional, Advisory Role: Roche; Financial Interests, Personal and Institutional, Training: Roche; Financial Interests, Personal and Institutional, Principal Investigator: Roche; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Training: MSD; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Advisory Role: Takeda; Financial Interests, Personal, Training: Takeda; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Training: Pfizer; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Principal Investigator: Mirati. A.L. Moreno Vega: Non-Financial Interests, Personal and Institutional, Invited Speaker: PharmaMar; Non-Financial Interests, Personal and Institutional, Invited Speaker: Roche. L. León: Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Boehringer; Financial Interests, Personal, Expert Testimony: Sanofi; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal and Institutional, Advisory Board, Travel support: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca. M. Majem: Financial Interests, Personal, Speaker's Bureau: Sanofi; Financial Interests, Personal, Advisory Board: Sanofi; Financial